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The CB2 receptor is one of the components of the endogenous cannabinoid system,
a complex network of signaling molecules and receptors involved in the homeostatic
control of several physiological functions. Accumulated evidence suggests a role for
CB2 receptors in Alzheimer’s disease (AD) and indicates their potential as a therapeutic
target against this neurodegenerative disease. Levels of CB2 receptors are significantly
increased in post-mortem AD brains, mainly in microglia surrounding senile plaques,
and their expression levels correlate with the amounts of Aβ42 and β-amyloid plaque
deposition. Moreover, several studies on animal models of AD have demonstrated that
specific CB2 receptor agonists, which are devoid of psychoactive effects, reduce AD-like
pathology, resulting in attenuation of the inflammation associated with the disease but
also modulating Aβ and tau aberrant processing, among other effects. CB2 receptor
activation also improves cognitive impairment in animal models of AD. This review
discusses available data regarding the role of CB2 receptors in AD and the potential
usefulness of specific agonists of these receptors against AD.
Keywords: CB2 receptor, cannabinoids, Alzheimer, neuroinflammation, β-amyloid, tau, oxidative stress
OVERVIEW OF ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is an age-dependent neurodegenerative disorder characterized by slowly
progressive cognitive decline with fatal outcome. To date, no effective treatment is available.
Dementia due to AD occurs in one in nine people aged 65 and in about one in four at the age of 85
(Hebert et al., 2013). Prevalence is expected to grow in coming decades as the size and proportion of
the older population continue to increase due to the rise in life expectancy in developed countries
(Hebert et al., 2013).
AD is morphologically distinguished by the presence in the brain of senile plaques, mainly
composed of different species of fibrillar β-amyloid (Aβ) produced by the cleavage of the β-amyloid
precursor protein (APP), and neurofibrillary tangles composed of various isoforms of hyper-
phosphorylated and truncated tau protein. Senile plaques are surrounded by dystrophic neurites,
reactive astrocytes, and microglia. Neurofibrillary tangles first appear in selected nuclei of the brain
stem, and entorhinal and transentorhinal cortex, and then progress to the hippocampus and limbic
system, and finally to most of the telencephalon (Braak and Braak, 1991). The development and
progression of senile plaques does not parallel the evolution of tau pathology in sporadic AD (Thal
et al., 2002). Aβ and tau misfolded proteins compromise neural activity due to an increase in
Aso and Ferrer CB2 Receptors and AD
toxic function and/or loss of their normal function, thus
contributing to the decline of neuronal organization manifested
as synaptic dysfunction and neuronal death (Duyckaerts and
Dickson, 2011; Ferrer, 2012). A self-propagating process of
misfolded proteins has been suggested to explain disease
progression (Jucker and Walker, 2013). Aβ and misfolded tau
aggregate into seeds that are able to modify native proteins
causing them to aggregate and to form pathogenic assemblies in
a prion-like way (Meyer-Luehmann et al., 2006; Clavaguera et al.,
2009; Stöhr et al., 2012).
It is important to note that AD-related pathology begins
more than 20 years before the onset of dementia. First stages
of AD in which lesions are restricted to the brain stem and
inner parts of the temporal lobe are usually asymptomatic.
About 80% of individuals aged 65 present senile plaques
and/or neurofibrillary tangles in specific brain areas but only
about 5% of them suffer from dementia. This is an important
point as AD-related pathology is common in the elderly
but this does not inevitably lead to dementia. AD changes
restricted to the inner temporal lobe can progress slowly and
be well tolerated in some individuals. Only the accumulation
of lesions in certain individuals determines a progression of the
neurodegenerative disease, which leads to dementia once reached
determinate threshold (Ferrer, 2012). The slow progression of the
neurodegenerative process visualizes a putative temporal window
for therapeutic intervention. However, to date most therapeutic
interventions aimed at modifying a single pathological factor
(e.g., cholinergic dysfunction, inflammation, Aβ and/or tau
aberrant processing) have failed because of their limited benefit
or for safety reasons (Scheltens et al., 2016). Considering that
multiple alterations are concomitant to Aβ and tau aberrant
processing in AD (Ferrer, 2012), compounds with pleiotropic
activity which will target in parallel several processes that play
key roles in AD are expected to yield greater benefits than those
obtained by current therapies (Bolognesi et al., 2009; Frautschy
and Cole, 2010). Inflammation, mitochondrial dysfunction,
oxidative stress, and impaired function of degradation pathways
are the most prominent concomitant pathological events (Keller
et al., 2000; Ferrer, 2009; Sultana and Butterfield, 2010; López-
González et al., 2015), as briefly described in the following
paragraphs. These alterations are potential targets of therapeutic
intervention.
Inflammation has been proposed as a key factor in the
pathogenesis of AD. This is characterized by microglial
activation, reactive astrocytes and elevated expression of
cytokines and mediators of the inflammatory response. It has
been proposed that microglial activation in AD can have
beneficial and detrimental effects depending on the stage of the
disease. Thus, the acute microglial reaction aims at removing
the abnormal protein aggregates appearing at the early stages of
the disease. However, cumulative formation of aberrant protein
aggregates drives to chronic inflammation which has detrimental
consequences due to the sustained exposure to chemokines,
cytokines and other inflammatory mediators (Heneka et al.,
2015). Conversion of microglia from detrimental (M1) to
beneficial (M2) phenotype may be achieved by modulation
of pro-inflammatory signaling pathways such as the NLRP3
inflammasome (Heneka et al., 2013). Similar to microglial
cells, astrocytes contribute to inflammation in AD by releasing
cytokines, interleukins, nitric oxide (NO), and other toxic
molecules in response to Aβ exposure at the time they also
participate in the internalization and degradation of Aβ (Heneka
et al., 2015). However, anti-inflammatory treatments failed to
produce beneficial effects in patients with severe cognitive
impairment and dementia. This fact is probably due to the fact
that inflammatory responses in AD differ not only depending on
the stage of the disease but also on the region involved (López-
González et al., 2015). That means that inflammatory responses
in some regions have a beneficial phenotype whereas they have
a deleterious phenotype in other regions in the same individual,
thus stressing the need to identify new regulators or modulators
of the inflammatory response that can be adapted to specific
molecular targets (López-González et al., 2015).
Altered mitochondria are also key factors in the pathogenesis
of AD. This includes impaired energy metabolism and increased
production of free radicals with subsequent oxidative and
nitrosative damage affecting lipids, proteins and nucleic acids
(Sultana and Butterfield, 2010). These alterations are already
observed in the entorhinal cortex at early stages of AD ultimately
leading to neuron exhaustion (Ferrer, 2009). Several studies in
AD transgenic mouse models support the potential beneficial
effect of compounds targeting mitochondrial dysfunction
although the clinical benefit of such drugs in humans is still not
known (Onyango et al., 2016).
Finally, another prominent concomitant pathological event
in AD is impaired function of degradation pathways (Keller
et al., 2000). Oxidative damage and some other pathological
events may alter protein structure and function in AD. These
modified proteins have to be removed to prevent their toxic
accumulation. However, the ubiquitin-proteasome system and
autophagy mechanisms are impaired due to the toxic effects of
Aβ and oxidative stress damage thus leading to the accumulation
of oxidized/unfolded proteins that may contribute to neuronal
loss (Tramutola et al., 2016).
ENDOGENOUS CANNABINOID SYSTEM:
A ROLE IN NEURODEGENERATIVE
DISEASES
Among the candidates to fulfill the requirements for novel
effective multi-target therapies against neurodegenerative
diseases are newly emerging compounds that target the
endogenous cannabinoid system (ECS; Aso and Ferrer, 2014;
Fagan and Campbell, 2014; Fernández-Ruiz et al., 2015). Interest
in the ECS derives from the pleiotropic activity of this complex
network of lipid molecules and receptors, which is involved in
homeostatic control of several physiological functions in brain
and other organs (Iannotti et al., 2016). The ECS is composed of
(i) at least two subtypes of cannabinoid Gi/o-coupled receptors,
CB1 and CB2 (Pertwee et al., 2010), (ii) certain endogenous
ligands, mainly arachidonoylethanolamine or anandamide
(AEA) and 2-arachidonoylglycerol (2-AG) derived from the
membrane phospholipids (Pertwee, 2015), (iii) several enzymes
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responsible for endocannabinoid biosynthesis and metabolism
(Ligresti et al., 2005), and (iv) molecules linked to the cellular
uptake and transport of certain endocannabinoids (Fowler,
2013). CB1 receptors are the most abundant cannabinoid
receptors and are located in brain, mainly in neurons but also
in glial cells, and in peripheral tissues (Hu and Mackie, 2015).
CB1 activity regulates important brain functions including
cognition and memory, emotion, motor control, feeding, and
pain perception, by modulating excitatory and inhibitory
neurotransmission (Wilson and Nicoll, 2002; Howlett, 2005).
Moreover, CB1 receptors mediate psychoactive effects of
cannabis derivatives (Maldonado et al., 2011). In contrast,
activation of CB2 receptors is not accompanied by psychoactive
effects (Buckley et al., 2000). CB2 was initially considered a
peripheral cannabinoid receptor because in situ hybridization
analysis revealed high levels of CB2 mRNA in spleen but levels
below the detection thresholds in brain. CB2 receptors were
demonstrated to modulate immune cell migration and the
release of cytokines in cells of the immune system (Cabral and
Griffin-Thomas, 2009). However, more recent findings have
shown that CB2 receptors are also present in other tissues
including the central nervous system (Atwood and Mackie,
2010). CB2 receptors are highly inducible and under certain
conditions are expressed in brain, mainly by microglia, with
levels increasing as these immune cells are activated. CB2
modulates microglial migration and infiltration into brain areas
with active neuroinflammation and degeneration (Walter et al.,
2003; Fernández-Ruiz et al., 2008). Moreover, CB2 receptors
are also present at detectable and functional levels in a subset
of neurons with increasing expression levels following injury
(Atwood and Mackie, 2010). Apart from the regulation of
inflammatory processes, some experimental designs also suggest
that CB2 receptors may play a role in nociception (Jhaveri et al.,
2007; Whiteside et al., 2007), gastrointestinal function (Wright
et al., 2008), neural progenitor cell proliferation and axon
guidance (Palazuelos et al., 2012; Duff et al., 2013), and synaptic
transmission (Kim and Li, 2015; Li and Kim, 2016), among other
functions. Most of the evidence comes from pharmacological
studies using specific CB2 agonists and antagonists, and from
genetically manipulated mice. However, the location of CB2
receptors mediating such effects is not conclusively documented.
As mentioned before, the ECS has a pleiotropic activity and is
able to modulate several alterations occurring during normal and
pathological aging, including protein misfolding, inflammation,
excitotoxicity, mitochondrial dysfunction, and oxidative stress
(Bilkei-Gorzo, 2012; Aso and Ferrer, 2014; Fagan and Campbell,
2014; Fernández-Ruiz et al., 2015). Evidence about the role of
ECS on aging derives from observations in genetic models.
Thus, deficiency in CB1 receptors contributes to acceleration of
aging (Bilkei-Gorzo et al., 2005, 2012) whereas deletion of the
endocannabinoid degrading enzyme FAAH enhances age-related
microglial activity and concomitant inflammatory responses in
brain (Ativie et al., 2015). In contrast, stimulation of certain
ECS components produces beneficial effects in experimental
models of neurodegenerative diseases (Aso and Ferrer, 2014;
Fagan and Campbell, 2014; Fernández-Ruiz et al., 2015). These
findings demonstrate a role for ECS in normal and pathological
aging that has sustained interest in developing therapies against
neurodegenerative diseases based on ECS modulation. Major
attention has been focused on the use of cannabinoid agonists,
but the psychoactive effects elicited by compounds targeting
CB1 receptors have served to limit their potential development
in clinical practice. For this reason, the study of specific CB2
agonists which are devoid of psychoactive effects is promising,
although detailed clinical evaluation is still needed (Atwood et al.,
2012).
CB2 RECEPTORS IN AD BRAINS
A few studies have addressed the analysis of CB2 contents in
AD brain but all of them have resulted in similar findings. A
significant increase in CB2 receptor levels has been found in post-
mortem AD brains mainly expressed in microglia surrounding
senile plaques (Benito et al., 2003; Ramírez et al., 2005; Solas et al.,
2013). Similarly, enhanced CB2 PET binding has been reported
in the brain in an animal model of AD (Savonenko et al., 2015).
In addition, CB2-specific staining is also observed in tangle-
like bearing neurons and in dystrophic neurites from frontal
cortex in AD (Ramírez et al., 2005). Interestingly, expression
levels of CB2 receptors correlate with Aβ42 levels and plaque
deposition although not with cognitive status (Solas et al., 2013),
thus suggesting that these pathogenic events induce CB2 receptor
expression. The strong induction of CB2 receptors in affected
microglia is therapeutically advantageous since it would permit
their selective activation in damaged tissues, thereby minimizing
the possibility of deleterious side effects. However, CB2 receptors
in AD brain are nitrosylated, probably as a consequence of
microglial activation and peroxynitrite radical formation, and
this may contribute to the impaired coupling of these receptors
to downstream effector signaling molecules (Ramírez et al.,
2005). Nevertheless, the functionality of CB2 receptors seems to
be at least partially preserved in AD according to the results
of pharmacological experiments carried out in AD models, as
described in the following sections.
CB2 RECEPTOR AS A THERAPEUTIC
TARGET IN AD: EVIDENCE FROM
EXPERIMENTAL MODELS
During the last decade, a number of studies have provided
experimental evidence about the potential therapeutic properties
of compounds targeting CB2 receptors in cellular and animal
models that mimic a variety of AD-related changes. A summary
of pharmacological findings supporting this hypothesis is
shown in Table 1. Moreover, at least three different genetically
manipulatedmurinemodels have recently been created to further
demonstrate a role for CB2 receptors in this neurodegenerative
disease (Table 2). Most of these assays are focused on the
potential benefit derived from the well-known anti-inflammatory
properties of CB2 agonists, but some of them also reveal
the capacity of CB2 receptors to modulate Aβ and hyper-
phosphorylated tau levels, among other molecular alterations.
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TABLE 1 | Pharmacological evidence of CB2 receptor as a therapeutic target in AD.
References AD model Compound acting on
CB2 receptors
CB2-mediated effect
Ehrhart et al., 2005 Aβ1−42 JWH-015 ↓ IFN-γ-mediated CD40 expression
Microglial cells culture ↓ TNF-α production
↑ Phagocytosis of Aβ
↓ NO
Ramírez et al., 2005 Aβ25−35 and Aβ1−40 HU-210 ↑ Neuronal survival
Microglial rat primary culture WIN55,212-2 ↓ Microglial reactivity to Aβ
Neuronal rat primary culture JWH-133 ↓ TNF-α levels
Adult rats (i.c.v. injection) ↑ Cognitive performance
Eubanks et al., 2006 Aβ1−40 1
9-THC AchE inhibition
↓ Aβ aggregation
(No direct demonstration of CB2 involvement)
Esposito et al., 2006 Aβ1−42 WIN55,212-2 = iNOS levels
C6 rat glioma cells JWH015 = NO production
PC12 neurons SR144528 = Phosphorylated tau levels
Esposito et al., 2007 Aβ1−42 JWH-015 ↑ Aβ-induced astrocytic proliferation (CB2 agonist)
C6 rat glioma cells SR144528 ↓ Aβ-induced astrocytic proliferation (CB2 antagonist)
Adult rats (cortical injection)
Tolón et al., 2009 Aβ1−42 JWH-015 ↑ Aβ plaque removal
THP1 human macrophages SR144528 ↑ Aβ Phagocytosis
U373 human astrocytoma
Human AD tissue sections
Martín-Moreno et al., 2011 Aβ1−42 JWH-133 ↓ ATP-induced increase in [Ca
2+]i
N13 and BV-2 microglial cells WIN55,212-2 ↑ Microglia migration
Rat primary microglia culture HU-308 ↓ NO production
Adult mice (i.c.v. injection) SR144528 ↑ Cognitive performance (no direct demonstration of
CB2 involvement)
↓ TNF-α and IL-6 expression (no direct demonstration of
CB2 involvement)
Fakhfouri et al., 2012 Aβ1−42 WIN55,212-2 ↑ Cognitive performance
Adult rats (hippocampal injection) SR144528 ↓ TNF-α and nuclear NF-kB levels
↓ Active caspase 3 levels and TUNEL-positive neurons
Martín-Moreno et al., 2012 TgAPP-2576 mice JWH-133 ↑ Cognitive performance
WIN55,212-2 ↑ Glucose uptake in brain
↓ Microglial response to Aβ
↓ Aβ deposition
↓ TNF-α and COX-2 levels
↑ Aβ transport across choroid plexus
Aso et al., 2013 APP/PS1 mice JWH-133 ↑ Cognitive performance
↓ Microglial response to Aβ
↓ Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, and
IFN-γ)
↓ Tau hyperphosphorylation around plaques
↓ Oxidative stress damage around plaques
Wu et al., 2013 Aβ1−40 MDA7 ↓ Expression of microglia and astrocyte markers
Adult rats (hippocampal injection) ↓ Secretion of interleukin-1β
(Continued)
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TABLE 1 | Continued
References AD model Compound acting on
CB2 receptors
CB2-mediated effect




Bachmeier et al., 2013 Primary human brain microvascular CB13 ↑ Aβ transport across blood brain barrier
endothelial cells AM630
Adult mice (Caudate putamen injection)
Chen et al., 2013 5xFAD APP mice 19-THC ↓ Aβ deposition
↓ Number of degenerated neurons
(No direct demonstration of CB2 involvement)
Janefjord et al., 2014 Aβ1−42 JWH-015 ↓ Aβ fibrillisation (no direct demonstration of CB2 involvement)
Neuroblastoma SH-SY5Y cells 19-THC = Cell viability after Aβ1−42 exposure
BV-2 microglial cells ↑ Cell viability after LPS exposure




(No direct demonstration of CB2 involvement)
Aso et al., 2015 APP/PS1 mice 19-THC ↑ Cognitive performance
↓ Astroglial response to Aβ
(No direct demonstration of CB2 involvement)
Köfalvi et al., 2016 TgAPP-2576 mice JWH-133 ↑ Glucose uptake in brain
WIN55,212-2
AM630
Anti-Inflammatory Effects of CB2 Receptor
Activity
Inflammation is common in most neurodegenerative diseases
including AD, and it may contribute to progressive neuronal
damage. Microglia play a major role in neuroinflammation.
Activated microglia produce cytokines and mediators of
inflammatory response which, in combination with neurons
and astrocytes, create a complex cytokine cycle with deleterious
consequences in brain when sustained over time (Heneka
et al., 2014; McGeer and McGeer, 2015). CB2 receptors, mainly
expressed in microglia, inhibit microglia-mediated neurotoxicity
by reducing the production of pro-inflammatory molecules and
by modulating macrophage migration in several pathological
conditions (Cabral and Griffin-Thomas, 2009). In addition, CB2
activity facilitates the transformation of microglial cells from the
M1 to M2 phenotype which is suggested to favor phagocytosis
and reparative mechanisms (Mecha et al., 2015). As summarized
in Table 1, a number of studies have shown anti-inflammatory
effects of CB2 agonists in different models of AD. Thus, in
vitro experiments have demonstrated that the selective agonists
JWH-015, JWH-133, and HU-308, and the mixed CB1–CB2
receptor agonists WIN55,212-2 and HU-210 reduce the release
of pro-inflammatory cytokines in microglial cell cultures exposed
to different species of the toxic Aβ peptide (Ehrhart et al.,
2005; Ramírez et al., 2005; Martín-Moreno et al., 2011). These
findings may be the result of CB2 agonists reducing microglial
activation by decreasing intracellular calcium concentration,
as demonstrated in microglial cell cultures (Martín-Moreno
et al., 2011). Moreover, JWH-133 and WIN55,212-2 promote
microglial migration, which facilitates the phagocytosis of
aggregated Aβ (Martín-Moreno et al., 2011). CB2 agonist JWH-
015 facilitates Aβ-induced astrocytic proliferation in cell culture
which participates in the inflammatory process as well (Esposito
et al., 2007). These findings have been corroborated in vivo
by the administration of selective CB2 and mixed CB1–CB2
receptor agonists to rats and mice inoculated with Aβ into the
brain, resulting in reduced levels of several pro-inflammatory
cytokines and decreased microglia reactivity to the Aβ insult
(Ramírez et al., 2005; Esposito et al., 2007; Martín-Moreno et al.,
2011; Fakhfouri et al., 2012; Wu et al., 2013). In some cases,
the specificity of CB2-induced effects has been demonstrated by
the co-administration of the selective CB2 antagonist SR144528
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TABLE 2 | Evidence about the role of CB2 receptors in AD obtained from genetically modified mice.
References Animal model AD-related characteristics
Chen et al., 2012 5xFAD/CB2(−/−) = Effect of a MAGL inhibitor on reducing astrocytes
Around plaques
Koppel et al., 2014 J20 APP/CB2(−/−) ↑ Soluble Aβ1−42
↑ Plaque deposition
↓ Total tau
↑ Microglia associated to plaques
Schmöle et al., 2015 APP/PS1/CB2(−/−) = Cognitive performance
= Plaque deposition
↓ Concentrations of soluble Aβ1−40and Aβ1−42
↓ Microglial cells and infiltrated macrophages
↓ Levels of pro-inflammatory chemokines and cytokines
Aso et al., 2016 APP/PS1/CB2(−/−) = Cognitive performance
= Cognitive improvement induced by 19-THC+CBD
↑ Soluble Aβ1−40
↑ Plaque deposition
= Tau phosphorylation around plaques
↓ Effect of 19-THC+CBD on reducing microglia around plaques
(Esposito et al., 2007; Martín-Moreno et al., 2011; Fakhfouri
et al., 2012). Moreover, transgenic mice bearing APP mutations
linked to familial AD exhibit a reduction in the number of
activated microglial cells surrounding Aβ deposits and in the
levels of pro-inflammatory cytokines after chronic treatment
with the selective CB2 receptor agonist JWH-133 (Martín-
Moreno et al., 2012; Aso et al., 2013). Considering that systemic
inflammation may exacerbate the progression of AD (Lim et al.,
2015) and that CB2 receptor is highly expressed in the peripheral
immune system (Atwood andMackie, 2010), it can be speculated
that systemic CB2-driven actions may be also beneficial in
AD.
Genetic models designed to unravel the role of CB2 receptors
in AD progression have produced divergent findings regarding
inflammatory responses (Table 2). A significant increase in the
number of activated microglia associated with plaques has been
reported in J20 APP transgenic AD mice lacking, in addition,
the CB2 receptor (Koppel et al., 2014). Knocking down CB2
receptor gene in APP/PS1mice results in a reduction of microglia
reactivity and in the levels of pro-inflammatory chemokines and
cytokines (Schmöle et al., 2015; Aso et al., 2016). Inhibition
of monoacylglycerol lipase (MAGL), one of the main enzymes
responsible for endocannabinoids degradation, results effective
at reducing astroglial reaction to amyloid plaques in 5xFAD
mice lacking CB2 receptor (Chen et al., 2012). However, the
effect induced by the combination of 19-THC+CBD is reduced
in APP/PS1 mice knockout for CB2 receptor (Aso et al.,
2016). Divergent results may be related to the differing genetic
backgrounds of mousemodels, but in any case they point to a role
for CB2 receptors in the control of microglial and inflammatory
responses to Aβ insults.
Modulation of Aβ and
Hyper-Phosphorylated Tau Processing
Anumber of studies have proposed a direct role for CB2 receptors
in the modulation of Aβ peptide levels in brain. Most of them
suggest the participation of CB2 receptors in Aβ clearance rather
than in Aβ production and aggregation. In this sense, activation
of CB2 receptors with the specific agonist JWH-015 facilitates Aβ
phagocytosis by human macrophages in brain sections obtained
from AD cases (Tolón et al., 2009) and by microglia in cell
culture (Ehrhart et al., 2005). Similarly, MDA7, another potent
synthetic CB2 agonist, promotes Aβ clearance in the brains of
Aβ-injected rats (Wu et al., 2013). JWH-133 and WIN55,212-2
favor Aβ transport through the choroid plexus in vitro (Martín-
Moreno et al., 2012). The facilitation of Aβ clearance across
the blood brain barrier has also been demonstrated using the
synthetic CB1–CB2 receptor agonist CB13 in in vitro and in vivo
models (Bachmeier et al., 2013). These findings may explain,
at least in part, the reduction in Aβ levels in APP transgenic
mice after chronic treatment with the agonists JWH-133 and
WIN55,212-2 (Martín-Moreno et al., 2012). A few reports have
also suggested a direct effect of the mixed CB1–CB2 agonist 19-
THC on the reduction of Aβ aggregation (Eubanks et al., 2006;
Cao et al., 2014; Janefjord et al., 2014) and on the promotion of
Aβ degradation (Chen et al., 2013). However, demonstration of
a direct involvement of CB1 or CB2 receptors is lacking in these
studies.
Further evidence of CB2 participation in Aβ processing
derives from the study of AD models with genetic deletion
of this receptor (Table 2). Two of the three models had
increased soluble Aβ levels and increased numbers of amyloid
plaques in adult mouse brains (Koppel et al., 2014; Aso et al.,
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2016). In the case of APP/PS1 mice lacking CB2 receptors,
the increased Aβ deposition observed may be related to the
reduced microglial reaction in their brains (Aso et al., 2016),
considering the role of CB2 activity in promoting microglial-
induced Aβ phagocytosis (Ehrhart et al., 2005; Tolón et al., 2009).
These observations reinforce the hypothesis that CB2 receptors
facilitate Aβ clearance whereas their absence results in greater
Aβ accumulation in brain. However, a slight reduction in soluble
Aβ and plaque content has been reported in aged AD mice
lacking CB2 receptors (Schmöle et al., 2015), suggesting that CB2
receptor participation in Aβ processing may vary along with the
progression of the neurodegenerative process.
A role for CB2 receptors in the modulation of tau hyper-
phosphorylation has also been proposed. Early studies performed
in cell cultures demonstrated that the mixed CB1–CB2 agonist
WIN55,212-2 inhibited tau protein hyper-phosphorylation in
Aβ-stimulated PC12 neuronal cells, but that this effect was
mediated mainly by CB1 receptors (Esposito et al., 2006).
Moreover, a specific CB2 agonist failed to modify tau hyper-
phosphorylation in the same experimental conditions (Esposito
et al., 2006).19-THC, amixed CB1–CB2 agonist, is able to reduce
tau phosphorylation in N2a/APPswe cells (Cao et al., 2014) but
no direct evidence has been found about the specific involvement
of CB2 receptors in such effect. It is worth noting that in vivo
experiments have demonstrated that chronic treatment with the
specific CB2 agonist JWH-133 significantly reduces tau hyper-
phosphorylation at the Thr181 site in the vicinity of Aβ plaques in
APP/PS1 mice (Aso et al., 2013). This effect may be explained by
concomitant decreased expression of active forms of GSK3β, p38
and SAPK/JNK in the vicinity of Aβ plaques in JWH-133-treated
APP/PS1 mice (Aso et al., 2013). In contrast, no difference in tau
hyper-phosphorylation at site Thr181 was observed in APP/PS1
mice lacking CB2 receptors (Aso et al., 2016), suggesting that the
activation of these receptors may avoid tau phosphorylation but
their absence does not alter the process of tau phosphorylation.
Yet J20 APP mice knocked out for the CB2 receptor gene show
decreased levels of total tau protein without modifications of
its phosphorylation state (Koppel et al., 2014). Considering all
these observations, it is clear that the role of CB2 receptors in
tau processing requires further investigation, as the available
information is variegated and not conclusive.
Other Effects: Neuronal Survival,
Anti-Oxidative, Glucose Metabolism, and
Cognition
Targeting CB2 receptors produces additional benefits in AD.
Thus, CB2 receptor agonists promote cell survival in the face
of Aβ insults in in vitro and in vivo models (Ramírez et al.,
2005; Fakhfouri et al., 2012; Chen et al., 2013; Janefjord et al.,
2014). Moreover, anti-oxidant effects have been reported for
compounds activating CB2 receptors. Specifically, two studies
have demonstrated that specific CB2 agonists reduce the
production of free radical NO induced by Aβ exposure in
microglial cell culture (Ehrhart et al., 2005; Martín-Moreno et al.,
2011), although these results have not been replicated in a glioma
cell line (Esposito et al., 2006). In vivo experiments also show that
activation of CB2 receptors reduces oxidative stress damage and
promotes anti-oxidative stress responses; chronic treatment with
JWH-133 reduces hydroxynonenal adducts derived from lipid
peroxidation and enhances the levels of superoxide dismutase
1 and superoxide dismutase 2 in the vicinity of plaques in
APP/PS1 mice (Aso et al., 2013). The mechanisms by which CB2
receptors mediate these anti-oxidant effects remain elusive. It
has been reported that the CB1–CB2 agonist ∆9-THC improves
mitochondrial function (Cao et al., 2014), thus presumably
contributing to a reduction in the production of free radicals,
but further study is needed to support this hypothesis. Additional
benefits of the activation of CB2 receptors in AD may derive
from the ability of these receptors to mediate glucose uptake in
brain (Martín-Moreno et al., 2012; Köfalvi et al., 2016), which
may counteract the well-known glucose metabolism deficit in AD
brains (Mosconi et al., 2008; Cohen and Klunk, 2014).
More importantly, CB2 selective and CB1–CB2 mixed agonists
prevent memory deficits in Aβ-injected rats and mice after
chronic administration (Ramírez et al., 2005; Martín-Moreno
et al., 2011; Fakhfouri et al., 2012; Wu et al., 2013) and improve
cognitive performance in two different transgenic mouse models
of AD (Martín-Moreno et al., 2012; Aso et al., 2013). The
mechanisms of action underlying cognitive improvement are
assumed to be multiple and likely related mainly to the capacity
of CB2 receptors to mitigate the harmful effects of several
molecules produced in AD brains. In fact, AD-like mice lacking
CB2 receptors display the same cognitive performance as the
corresponding transgenic control mice (Schmöle et al., 2015; Aso
FIGURE 1 | Schematic representation of main effects of CB2 receptor
activation reported in AD models. CB2 receptor agonists reduce the
release of pro-inflammatory molecules, facilitate Aβ clearance by promoting
microglia phagocytic phenotype, reduce Aβ neurotoxicity, and facilitate glucose
uptake. Moreover, CB2-mediated activity reduces oxidative stress damage
produced by reactive oxidative species (ROS) and tau hyper-phosphorylation.
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Taken together, the experimental observations discussed in
the present review indicate that AD induces CB2 receptor
expression and that targeting CB2 receptors has beneficial effects
in AD. Specifically, CB2 receptor agonists reduce inflammatory
responses linked to Aβ production and deposition, facilitate
Aβ clearance, increase cell viability in the presence of Aβ, and
promote glucose uptake in brain. Moreover, CB2 activity likely
reduces tau hyper-phosphorylation and oxidative stress damage
caused by Aβ peptides (Figure 1). As a result of the combination
of these effects, among others, CB2 receptor agonists induce
cognitive improvement in AD models.
Considering the evidence of pleiotropic activity and lack of
undesirable psychoactive effects of CB2 receptors, compounds
acting on such cannabinoid receptors represent a promising
therapy against AD. Nevertheless, there is still no information
regarding the efficacy or toxicity in human beings of compounds
specifically targeting CB2 receptors, which might exhibit some
side effects such as immune suppression (Pertwee, 2005). For
these reasons, progress toward clinical practice requires further
investigation.
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